Gene fusions can significantly impact cancer treatment strategies. For instance, the discovery of the BCR-ABL fusion gene led to the development of tyrosine kinase inhibitors like imatinib, which specifically target the abnormal protein produced by this fusion. Such targeted therapies often result in better outcomes and fewer side effects compared to traditional chemotherapy.
